A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

URL

https://www.nejm.org/doi/full/10.1056/NEJMoa1910993

Authors

Sabue Mulangu, Lori E. Dodd, Richard T. Davey, Jr., Olivier Tshiani Mbaya, Michael Proschan, Daniel Mukadi, Mariano Lusakibanza Manzo, Didier Nzolo, Antoine Tshomba Oloma, Augustin Ibanda, Rosine Ali, Sinaré Coulibaly, Adam C. Levine, Rebecca Grais, Janet Diaz, H. Clifford Lane, Jean-Jacques Muyembe-Tamfum, and the PALM Writing Group for the PALM Consortium Study Team

Published Date

December 12, 2019

Publication

New England Journal of Medicine (NEJM)

Organization

Institut National de Recherche Biomédical (Congo)

Additional Information

Funded by the National Institute of Allergy and Infectious Diseases and others; PALM ClinicalTrials.gov number, NCT03719586.

Medium

document

Topics

COVID-19,medical treatments,pharmaceuticals,remdesivir